Patisiran for ATTR Cardiomyopathy Gets FDA Panel Thumbs Up Patisiran for ATTR Cardiomyopathy Gets FDA Panel Thumbs Up

An FDA advisory committee voted 9 to 3 that the benefits of patisiran outweigh the risks for ATTR cardiomyopathy, but many questioned whether the benefit is clinically meaningful.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news